{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:50:58Z","timestamp":1768888258248,"version":"3.49.0"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<sec><title>BACKGROUND<\/title>The WHO recommends shorter TB preventive treatment (TPT) regimens and decentralised delivery models to improve effectiveness. This study evaluated the safety of a 3-month rifampicin-isoniazid (3RH) regimen administered by community\n health workers (CHWs) in households in Cameroon and Uganda.<\/sec><sec><title>METHODS<\/title>A cluster-randomised trial was conducted among child contacts of TB patients. We compared the safety of 3RH delivered by CHWs at home (intervention) vs standard-of-care,\n facility-based administration of 3RH. Safety outcomes included adverse events (AEs), serious adverse events (SAEs), and adverse reactions (ARs). We described the steps from symptom identification by CHWs to classification by a clinician.<\/sec><sec><title>RESULTS<\/title>Of\n 1,316 children initiated on 3RH, AEs were reported in 8.7% (81\/936) in the intervention arm versus 11.3% (43\/380) in the standard-of-care arm, P<\/jats:italic> = 0.15. Overall, 37 SAEs occurred in 36 children, all non-medication related. There were 16 ARs reported, occurring in 1.0% (9\/936) of children\n in the intervention arm and 1.6% (6\/380) in the standard-of-care arm, P<\/jats:italic> = 0.22. During 4,608 follow-up visits, 21 children reporting AR symptoms were identified by CHWs, 16 were assessed by clinicians, and 4 ARs were confirmed.<\/sec><sec><title>CONCLUSIONS<\/title>The\n 3RH regimen was safe, including when administered by trained CHWs in community settings, supporting its use in decentralised healthcare models.<\/sec><\/jats:p>","DOI":"10.5588\/ijtld.24.0311","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:53:02Z","timestamp":1738385582000},"page":"67-74","source":"Crossref","is-referenced-by-count":1,"title":["Safety of 3-month rifampicin-isoniazid TPT in child household contacts in a community-based intervention"],"prefix":"10.5588","volume":"29","author":[{"given":"B.","family":"Tchakounte Youngui","sequence":"first","affiliation":[{"name":"University of Montpellier, TransVIHMI, Institut de Recherche pour le D\u00e9veloppement (IRD), Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Montpellier, France;, Department of Public Health Evaluation,\n Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaound\u00e9, Cameroun;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.K.","family":"Tchounga","sequence":"additional","affiliation":[{"name":"Department of Public Health Evaluation, Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaound\u00e9, Cameroun;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Atwine","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Epicentre Research Center, Mbarara, Uganda;, Department of Clinical Research, Soar Research Foundation, Mbarara, Uganda;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vasiliu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Global TB Program, Baylor College of Medicine, Houston, TX, USA;, Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany;, German Center for Infection Research (DZIF), Partner Site Hamburg-L\u00fcbeck-Borstel-Riems,\n Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Cuer","sequence":"additional","affiliation":[{"name":"University of Montpellier, TransVIHMI, Institut de Recherche pour le D\u00e9veloppement (IRD), Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Montpellier, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Simo","sequence":"additional","affiliation":[{"name":"Department of Public Health Evaluation, Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaound\u00e9, Cameroun;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Okello","sequence":"additional","affiliation":[{"name":"Elizabeth Glaser Pediatric AIDS Foundation, Kampala, Uganda;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tchendjou","sequence":"additional","affiliation":[{"name":"Department of Public Health Evaluation, Research, Elizabeth Glaser Pediatric AIDS Foundation, Yaound\u00e9, Cameroun;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kuate Kuate","sequence":"additional","affiliation":[{"name":"National Tuberculosis Programme, Ministry of Health, Cameroon;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Turyahabwe","sequence":"additional","affiliation":[{"name":"Tuberculosis Leprosy Control, Ministry of Health, Uganda;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cohn","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Murdoch Children\u2019s Research Institute, University of Melbourne, Royal Children\u2019s Hospital, Melbourne, VIC, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Casenghi","sequence":"additional","affiliation":[{"name":"Elizabeth Glaser Pediatric AIDS Foundation, Geneva, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bonnet,","sequence":"additional","affiliation":[{"name":"University of Montpellier, TransVIHMI, Institut de Recherche pour le D\u00e9veloppement (IRD), Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Montpellier, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2025\/00000029\/00000002\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:53:06Z","timestamp":1738385586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.24.0311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"alternative-id":["1027-3719(20250201)29:2L.67;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.24.0311","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}